A Phase I Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients with Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

In this phase I study, FHD-609, a degrader of bromodomain-containing protein 9 (BRD9) was evaluated for treating patients with advanced synovial sarcoma or SMARCB1-deficient tumors. The study determined the maximum tolerated dose, and demonstrated extensive BRD9 degradation in tumor tissue which corresponded to the downregulation of cancer cell proliferation gene sets.

CellCarta is proud to have contributed to this work, performing BRD9 degradation analysis in T cells from PBMC samples. This approach involved immunophenotyping major PBMC populations with a cell-surface antibody cocktail, followed by intracellular detection of BRD9. CellCarta also performed the flow data analysis using CellEngine, our in-house software.

Bullet points:

• Multinational, multicenter phase I study
• Study evaluated the safety and tolerability of a targeted BRD9 degrader in patients with advanced synovial sarcoma and SMARCB1-deficient tumors.
• Work determined maximum tolerated dose and showed preliminary clinical activity
• CellCarta is proud to have supported this work through analysis of PBMC samples via flow cytometry and flow cytometry data analysis with CellEngine

View the full publication